FDA Draft Guidance Maps Payor Strategy For Psychedelics
In June, the U.S. Food and Drug Administration issued its first revision to the guidance governing manufacturer communications with payors in eight years.[1]...To view the full article, register now.
Already a subscriber? Click here to view full article